Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council of Australia (1173958, 1132519, 1159593)
Naito Foundation
Leukemia Foundation of Australia (SERP)
- License Information
-
More Information
Article History
Received: 5 June 2020
Accepted: 28 July 2020
First Online: 12 August 2020
Consent for publication
: Not applicable
: Mark J. Smyth has research agreements with Bristol Myers Squibb and Tizona Therapeutics and serves on the Scientific Advisory Board of Tizona Therapeutics and Compass Therapeutics.
